Stocks
CNS Pharmaceuticals, Inc.CNSP
NASDAQHealthcareBiotechnology$4.97
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing treatments for central nervous system cancers, with its lead candidate, berubicin, an anthracycline designed to cross the blood-brain barrier for glioblastoma. Investors track the stock for its progress in Phase 2 trials and potential in an area with high unmet medical need.
52W Range: $1.90-$10.54
Congressional Interest in CNS Pharmaceuticals, Inc. (CNSP)
No congressional trades have been disclosed for CNS Pharmaceuticals, Inc. (CNSP) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CNSP?
No congressional trades found for this stock.